Artemis Medicare Services Limited has reported a significant utilization of Rs. 330 crore for the quarter ending September 30, 2025, related to its Preferential Issue of Compulsorily Convertible Debentures. The details were disclosed in a Monitoring Agency Report released by CARE Ratings Limited on November 11, 2025. This report was subsequently reviewed by the company's Audit Committee, confirming that there were no deviations from the intended use of the proceeds as outlined in the Offer Document. The monitoring agency's role included verifying the proper allocation of funds, ensuring compliance with Securities and Exchange Board of India (SEBI) regulations.

In the monitoring report, CARE Ratings confirmed that all utilized funds adhered to the disclosures made in the Offer Document, with no material deviations observed. The agency utilized various sources of information, including a Chartered Accountant's Certificate and management certifications, to substantiate its findings. Notably, the report indicated that there was no utilization recorded during the quarter, which aligns with the company’s strategic planning and capital expenditure objectives. The report is publicly available on Artemis’s investor relations website.

Artemis Medicare Services continues to maintain transparency and compliance in its financial reporting. The management has assured that all government approvals are in place, and the proceeds are earmarked for future acquisitions and capital expenditures. The absence of unfavorable events affecting the viability of these projects further strengthens investor confidence. The company's proactive engagement with monitoring agencies underscores its commitment to good governance and adherence to financial regulations, which will be critical as it progresses into the next phases of its growth strategy.